Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06KTJ
|
|||
| Former ID |
DIB006257
|
|||
| Drug Name |
TAK-659
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [1] | |
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [2] | ||
| Company |
Millennium pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H21FN6O
|
|||
| Canonical SMILES |
CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)NC4CCCCC4N
|
|||
| InChI |
1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1
|
|||
| InChIKey |
MJHOMTRKVMKCNE-NWDGAFQWSA-N
|
|||
| CAS Number |
CAS 1312691-33-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02323113) Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health. | |||
| REF 3 | J Clin Oncol 32:5s, 2014 (suppl; abstr 8580). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.